Edwards Lifesciences Corporation $EW Shares Bought by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. increased its position in Edwards Lifesciences Corporation (NYSE:EW) by 57.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,880 shares of the medical research company’s stock after buying an additional 13,820 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Edwards Lifesciences were worth $2,946,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Rosenberg Matthew Hamilton bought a new stake in Edwards Lifesciences in the second quarter worth about $28,000. True Wealth Design LLC boosted its position in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares in the last quarter. NewSquare Capital LLC grew its stake in shares of Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after purchasing an additional 134 shares during the last quarter. Rakuten Securities Inc. raised its holdings in shares of Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Finally, Hantz Financial Services Inc. raised its holdings in shares of Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after purchasing an additional 164 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

EW opened at $79.29 on Thursday. The firm has a market capitalization of $46.01 billion, a P/E ratio of 43.33, a PEG ratio of 2.98 and a beta of 0.94. The stock has a fifty day moving average of $83.73 and a 200-day moving average of $81.13. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. During the same period in the previous year, the firm posted $0.59 earnings per share. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,370,184.06. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total transaction of $971,384.40. Following the transaction, the vice president directly owned 31,870 shares in the company, valued at $2,729,984.20. The trade was a 26.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 43,804 shares of company stock valued at $3,699,082 over the last three months. 1.29% of the stock is owned by corporate insiders.

Trending Headlines about Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Company-level outlook: Edwards raised its 2026 profit outlook and told investors it expects demand to remain robust for its artificial heart valves and structural?heart devices, a primary reason shares rallied after hours. Reuters: Forecasts 2026 profit above estimates
• Positive Sentiment: Quarterly guidance beat: EW provided Q1 2026 EPS guidance of $0.700–$0.760 (above consensus ~ $0.69) and reiterated revenue guidance, which helped calm near?term uncertainty. Business Wire: Q4 results and guidance
• Positive Sentiment: Revenue momentum: Q4 sales grew ~13.3% YoY, led by TAVR (double?digit growth) and strong TMTT performance — evidence of sustained demand for core products. Zacks: Revenues up Y/Y; TAVR/TMTT strength
• Positive Sentiment: Analyst support: Several firms reiterated Buy/Overweight ratings and raised targets (Wells Fargo to $100; BTIG reaffirmed $103; other firms reiterated conviction), boosting sentiment and providing upside to estimates. TipRanks: Multiple buy ratings and analysis
• Neutral Sentiment: Options/short-term trade view: Some commentators see the post?earnings weakness as a contrarian/options opportunity for bulls now that key earnings uncertainty is cleared. Benzinga: Options contrarian trade
• Neutral Sentiment: Earnings call detail available: Management commentary from the Q4 call/earnings transcript provides more color on margin drivers and product cadence for investors who want to dig deeper. Seeking Alpha: Q4 earnings call transcript
• Negative Sentiment: Profitability pressures and EPS miss: Adjusted EPS (~$0.58) missed consensus and GAAP profitability showed sizeable year?over?year declines (operating and net income hit), reflecting margin headwinds and one?time items that investors should watch. Quiver: GAAP profit and EPS pressure

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, December 17th. Citigroup reissued a “buy” rating and set a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Royal Bank Of Canada lifted their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.